5 603

Cited 9 times in

Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer

 Seungtaek Lim  ;  Byoung Chul Cho  ;  Ji Ye Jung  ;  Gun Min Kim  ;  Se Hyun Kim  ;  Hye Ryun Kim  ;  Han Sang Kim  ;  Sun Min Lim  ;  Ji Soo Park  ;  Jun Ho Lee  ;  Darae Kim  ;  Eun Young Kim  ;  Moo Suk Park  ;  Young Sam Kim  ;  Se Kyu Kim  ;  Joon Chang  ;  Joo Hang Kim 
 LUNG CANCER, Vol.80(3) : 313-318, 2013 
Journal Title
Issue Date
Adult ; Aged ; Camptothecin/administration & dosage ; Camptothecin/adverse effects ; Camptothecin/analogs & derivatives* ; Cisplatin/administration & dosage* ; Cisplatin/adverse effects ; Disease-Free Survival ; Drug-Related Side Effects and Adverse Reactions ; Female ; Follow-Up Studies ; Humans ; Male ; Neoplasm Metastasis/drug therapy* ; Neoplasm Metastasis/pathology ; Neoplasm Staging ; Small Cell Lung Carcinoma/drug therapy* ; Small Cell Lung Carcinoma/pathology ; Young Adult
Extensive disease ; Small cell lung cancer ; Chemotherapy ; Belotecan ; Cisplatin ; Response
The aim of this study was to investigate the efficacy and safety of belotecan in combination with cisplatin in patients with previously non-treated extensive stage small cell lung cancer. A total of 42 patients were enrolled and treated with combination of belotecan 0.5 mg/m2 on daily basis throughout day 1–4 and cisplatin 60 mg/m2 on day 1 of a 3-week cycle, up to 6 cycles. Treatment was continued until the completion of 6 cycles of the chemotherapy, disease progression, detection of unacceptable toxicity, withdrawal of the consent, or death of the patient. Response was assessed every 2 cycles of chemotherapy by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. Toxicity was assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 3.0. The overall response rate was 73.8% in an intention to treat population and 83.9% in the evaluable patients. With the median follow up of 9.9 months, the median progression free survival was 6.9 months (95% CI, 6.6–7.2 months), and median overall survival was 11.2 months (95% CI, 9.9–12.5 months). The frequently reported grade ≥ 3 toxicities were neutropenia (90.2%), thrombocytopenia (63.4%), and anemia (34.1%). Febrile neutropenia was reported in 16 patients (39.0%). Although most of non-hematologic toxicities were grade 1 or 2, there were 4 patient deaths caused by pneumonia complicated by septic shock. Belotecan and cisplatin combination chemotherapy demonstrated a promising efficacy in ED SCLC patients. But, the hematologic toxicity of this regimen requires considerable amount of attention.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pharmacology (약리학교실) > 1. Journal Papers
Yonsei Authors
Kim, Gun Min(김건민) ORCID logo https://orcid.org/0000-0001-9167-8682
Kim, Da Rae(김다래)
Kim, Se Kyu(김세규)
Kim, Se Hyun(김세현)
Kim, Young Sam(김영삼) ORCID logo https://orcid.org/0000-0001-9656-8482
Kim, Eun Young(김은영) ORCID logo https://orcid.org/0000-0002-3281-5744
Kim, Joo Hang(김주항)
Kim, Han Sang(김한상) ORCID logo https://orcid.org/0000-0002-6504-9927
Kim, Hye Ryun(김혜련) ORCID logo https://orcid.org/0000-0002-1842-9070
Park, Moo Suk(박무석) ORCID logo https://orcid.org/0000-0003-0820-7615
Park, Ji Soo(박지수) ORCID logo https://orcid.org/0000-0002-0023-7740
Lee, Jun Ho(이준호)
Lim, Sun Min(임선민)
Lim, Seung Taek(임승택)
Chang, Joon(장준) ORCID logo https://orcid.org/0000-0003-4542-6841
Jung, Ji Ye(정지예) ORCID logo https://orcid.org/0000-0003-1589-4142
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.